Abiomed (Nasdaq: ABMD) reported earnings on May 16. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q4), Abiomed beat expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share improved.

Margins grew across the board.

Revenue details
 Abiomed notched revenue of $37.3 million. The eight analysts polled by S&P Capital IQ predicted a top line of $34.9 million on the same basis. GAAP reported sales were 31% higher than the prior-year quarter's $28.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.06. The six earnings estimates compiled by S&P Capital IQ predicted $0.07 per share. GAAP EPS were $0.06 for Q4 compared to -$0.05 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 81.8%, 230 basis points better than the prior-year quarter. Operating margin was 7.9%, 1,280 basis points better than the prior-year quarter. Net margin was 6.9%, 1,310 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $36.2 million. On the bottom line, the average EPS estimate is $0.03.

Next year's average estimate for revenue is $153.5 million. The average EPS estimate is $0.22.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 84 members out of 115 rating the stock outperform, and 32 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give Abiomed a green thumbs-up, and nine give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abiomed is outperform, with an average price target of $23.00.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Abiomed the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.